At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Luminor DCB and Angiolite DESdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Physician Initiated, Prospective, Non-Randomized Multi-center Trial, Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia
In Brief
A clinical study evaluating Luminor DCB and Angiolite DES for Critical Limb Ischemia. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
This study aims to evaluate the 12 month outcome of the mono- or combination therapy with iVascular Luminor DCB and Angiolite DES for treatment of TASC C and TASC D long tibial occlusive disease, presenting with critical limb ischemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Limb Ischemia
CountriesSingapore
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedAug 2019
Primary CompletionMar 2020
Study CompletionSep 2020
TodayJul 2026
First PostedAug 29, 2019
Enrollment StartDec 27, 2018
Primary CompletionMar 10, 2020
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.8 years ago
Interventions
Luminor DCB and Angiolite DESdevice
Patient to undergo angioplasty with Luminor DCB and Angiolite DES